What Happened?
Montreal, PQ-based Hyasynth-Bio Appointed Kevin Chen as Co Founder and Chief Executive Officer
About the Company
Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.
About the Person
Kevin Chen is Co Founder and Chief Executive Officer at Hyasynth Bio. Previously, Kevin held various senior HR leadership roles in the industry.
Info Source
News
Short Profile